RBC Capital Downgrades Perspective Therapeutics to Sector Perform, Lowers Price Target to $4
Benzinga Newsdesk 6 days ago
Analyst RatingsNewsDowngradesPrice Target
RBC Capital analyst Leonid Timashev downgrades Perspective Therapeutics (AMEX:CATX) from Outperform to Sector Perform and lowers the price target from $14 to $4.
RBC Capital analyst Leonid Timashev downgrades Perspective Therapeutics (AMEX:CATX) from Outperform to Sector Perform and lowers the price target from $14 to $4.